This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Fasoracetam
- DrugBank Accession Number
- DB16163
- Background
Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without Mglur Mutations).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Fasoracetam (DB16163)
- Weight
- Average: 196.25
Monoisotopic: 196.121177763 - Chemical Formula
- C10H16N2O2
- Synonyms
- Fasoracetam
- External IDs
- AEVI-001
- LAM-105
- NS-105
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 42O8UF5CJB
- CAS number
- 110958-19-5
- InChI Key
- GOWRRBABHQUJMX-MRVPVSSYSA-N
- InChI
- InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
- IUPAC Name
- (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
- SMILES
- O=C([C@H]1CCC(=O)N1)N1CCCCC1
References
- General References
- Not Available
- External Links
- KEGG Compound
- C13311
- ChemSpider
- 171980
- ChEBI
- 31592
- ChEMBL
- CHEMBL2106179
- ZINC
- ZINC000003779713
- Wikipedia
- Fasoracetam
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Attention Deficit Hyperactivity Disorder (ADHD) 2 somestatus stop reason just information to hide 1 Completed Treatment Attention Deficit Hyperactivity Disorder (ADHD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 108.0 mg/mL ALOGPS logP 0.27 ALOGPS logP -0.4 Chemaxon logS -0.26 ALOGPS pKa (Strongest Acidic) 11.65 Chemaxon pKa (Strongest Basic) -2.2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 49.41 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 51.85 m3·mol-1 Chemaxon Polarizability 20.69 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03ea-4900000000-4dc44c9bd30cbc8034e5 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-1900000000-bbe0eac8b23379f80079 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0016-9100000000-be47d754d0f8b82d0891 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9500000000-f6095b548bc1683942ce Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0ldi-9700000000-3784d4da52ec3bd6a9ea Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-000x-9300000000-a63bd295ef0ce9d81f19 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 147.9991726 predictedDarkChem Lite v0.1.0 [M-H]- 144.61931 predictedDeepCCS 1.0 (2019) [M+H]+ 148.9404726 predictedDarkChem Lite v0.1.0 [M+H]+ 146.9497 predictedDeepCCS 1.0 (2019) [M+Na]+ 152.9459 predictedDeepCCS 1.0 (2019)
Drug created at December 15, 2020 18:14 / Updated at February 21, 2021 18:55